22 results about "Trachoma" patented technology

The application provides a primer probe composition and application thereof in detection of urogenital tract pathogens, and relates to the technical field of biology. The primer probe composition comprises a chlamydia trachomatis primer probe pair with sequences shown in SEQ ID NO:1-6; a gonococcus primer probe pair with sequences shown in SEQ ID NO:7-9; and a mycoplasma genitalium primer probe pair with sequences shown in SEQ ID NO:10-12. The primer probe pairs in the primer probe composition do not have significant cross interference, the lower limit of detection can be as low as 20 copies / reaction, 200 copies / mL, and the problem that the lower limit of detection of the urogenital tract pathogens in the prior art needs to be reduced is solved.

The utility model discloses a sand hole plugging device for an underground air and water pipeline. The sand hole plugging device comprises two hoops, each group of connecting lugs comprises two connecting lugs, the two groups of connecting lugs are fixedly connected to the surfaces of the two hoops respectively, and through holes are formed in the surfaces of the connecting lugs. According to the sand hole plugging device for the underground air and water pipeline, the surface of the pipeline can be surrounded by the two hoops, the sand hole can be rapidly plugged through the plugging assembly, the plugging effect is good, operation is easy and convenient, the purpose of rapid installation can be achieved, the plugging time is saved, and pipeline operation can be rapidly recovered when needed; the sealing air bag can be automatically bulged through the plugging assembly after the connecting rod is inserted into the trachoma and enters the pipeline, the gap between the connecting rod and the inner wall of the trachoma is filled with the bulged sealing air bag, the plugging effect is further improved, different hole diameters of the trachoma can be adapted, and the plugging effect is improved.

The invention discloses a primer probe group and a kit for joint detection of mycoplasma genitalium, ureaplasma urealyticum and chlamydia trachomatis, and belongs to the technical field of molecular biological detection. The primer probe group comprises a primer probe group A for directly detecting a mycoplasma genitalium mgpB gene, a primer probe group B for directly detecting a ureaplasma urealyticum ureB gene and a primer probe group C for directly detecting a chlamydia trachomatis ompA gene; the kit comprises a PCR (Polymerase Chain Reaction) reaction solution and the primer probe group. Nucleic acid extraction is not needed, the detection cost is greatly reduced, the experiment time is shortened, meanwhile, the specificity and accuracy are still guaranteed, meanwhile, the sensitivity is improved, and the method has wide application prospects in the fields of non-gonococcal genital tract infection main pathogen detection, infertility and prenatal and postnatal care screening and the like. And the kit has important significance on clinical diagnosis, early treatment and prevention of diseases, prevalence and the like.

The invention relates to the technical field of molecular biology, and discloses an LAMP (loop-mediated isothermal amplification) primer group and a kit for detecting three items (Uu, CT and NG) of venereal diseases. The LAMP primer group disclosed by the invention comprises a first primer group for targeting a ureaplasma urealyticum UreB gene, a second primer group for targeting a chlamydia trachomatis gyrA gene and a third primer group for targeting a gonococcus glnA gene. The LAMP primer group provided by the invention has good thermal stability, is suitable for an LAMP amplification detection system at a high temperature of 70 DEG C, reduces non-specific binding, and has good detection sensitivity and specificity. The LAMP primer group and the kit provided by the invention provide an innovative solution for accurate diagnosis of sexually transmitted diseases.

The application provides a monoclonal antibody of a Chlamydia trachomatis Pgp3 protein and application thereof, and the monoclonal antibody comprises a heavy chain variable region CDR1, a heavy chain variable region CDR2 and a heavy chain variable region CDR3 with the amino acid sequences shown in SEQ ID NO. 1, 2 and 3 respectively, and a light chain variable region CDR1, a light chain variable region CDR2 and a light chain variable region CDR3 with the amino acid sequences shown in SEQ ID NO. 4, 5 and 6 respectively. Experimental researches prove that the monoclonal antibody of the Chlamydia trachomatis Pgp3 protein can effectively inhibit infection of Chlamydia trachomatis in a mouse genital tract, and reduce occurrence of oviduct edema.

The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.

The invention belongs to the technical field of in-vitro diagnostic reagents for rapid detection of human pathogenic microorganisms, and particularly relates to a kit for rapid combined detection of multiple pathogen nucleic acids related to a dyspnea pregnancy outcome and application of the kit. The pathogen is selected from one or more of escherichia coli, candida albicans, candida glabrata, group B streptococcus, streptococcus gonorrhoeae, chlamydia trachomatis or ureaplasma urealyticum, and the kit comprises a pathogen and lactobacillus rapid detection micro-fluidic chip. A primer group for detecting the pathogen and the lactic acid bacillus nucleic acid and an array consisting of an amplification control and a blank control are fixed on the micro-fluidic chip. According to the present invention, the microfluidic chip rapid detection technology and the nucleic acid amplification technology are adopted to achieve the purposes of rapid detection and multiple detection so as to rapidly and conveniently determine the poor prognosis risk of the pregnant woman at present, timely take the specific measures, and avoid the occurrence of the poor prognosis.

The invention relates to a method for detecting the presence of at least two pathogens in a sample, wherein additionally subtypes and / or variant-derived properties such as treatment susceptibility are determined. The method may be a polymerase chain reaction and may be facilitated by a cartridge and dried reagents. The pathogens may be bacterial pathogens such as Chlamydia trachomatis and Neisseria gonorrhoeae. The invention further relates to a cartridge and / or a cartridge reader for performing the method of the invention.

The invention provides a primer composition for detecting chlamydia trachomatis, gonococcus and ureaplasma urealyticum and application of the primer composition, and relates to the technical field of nucleic acid determination or detection methods. The primer composition provided by the invention comprises a first primer and a second primer which are used for detecting chlamydia trachomatis, a third primer and a fourth primer which are used for detecting gonococcus, and a fifth primer and a sixth primer which are used for detecting ureaplasma urealyticum. The primer composition provided by the invention can realize the detection of the three pathogens, and has the characteristics of good specificity, high sensitivity and good repeatability. Based on the primer composition, an immunochromatography test strip detection technology is further combined, rapid and efficient detection of chlamydia trachomatis, gonococcus and ureaplasma urealyticum can be achieved, operation is easy, portability is achieved, and the primer composition can be used for home self-inspection.

The invention relates to a set of oligonucleotide primers, and kits and in vitro diagnostic devices comprising the set of oligonucleotide primers. The set of oligonucleotide primers, kits and in vitro diagnostic devices can be used in detecting Chlamydia trachomatis nucleic acid and diagnosing Chlamydia trachomatis infection with high sensitivity and specificity. The invention also relates to methods of loop-mediated isothermal amplification, methods of detecting Chlamydia trachomatis nucleic acid, and methods of diagnosing Chlamydia trachomatis infection using the set of oligonucleotide primers or the kits.

The invention belongs to the technical field of biology, and provides a chlamydia trachomatis and gonococci double-target immunochromatography detection method which comprises the following steps: introducing a dibenzocyclooctyne group to the tail end of lipopolysaccharide of the chlamydia trachomatis, introducing a trans-cyclooctene group into outer membrane protein of gonococci, and detecting the chlamydia trachomatis and gonococci double-target immunochromatography. In the chromatographic detection process, the antibody can form two non-interfering detection channels with an anti-lipopolysaccharide antibody containing an azide group and an anti-outer membrane protein antibody containing a tetrazine group. Through the improvement, the problem that a high-concentration antigen occupies a binding site or interferes with a chromatography process due to nonspecificity can be avoided, and high specificity and high sensitivity of detection are ensured.

The invention relates to a flora prediction model for detecting premature delivery risk and a kit and application thereof. Through early-stage mNGS data collection and analysis, premature related strains are obtained, and through a large number of experimental screening and optimization, a set of optimal primer probe group is finally determined. The invention relates to a premature delivery risk calculation method, which comprises the following steps of: selecting 12 floras, namely lactobacillus crispatus, lactobacillus gasseri, lactobacillus inertus, lactobacillus jensenii, escherichia coli, enterococcus faecalis, enterobacter aerogenes, group B hemolytic streptococcus, ureaplasma parvum, chlamydia trachomatis, diplococcus gonorrhoeae and gardnerella vaginalis, and establishing a fluorescent quantitative PCR (Polymerase Chain Reaction) method and a premature delivery risk calculation model aiming at the detection of the 12 floras. Compared with an existing detection method, the method is simple, convenient, rapid, high in sensitivity and high in specificity, the false positive and false negative risk is reduced, and the purpose of batch detection is achieved. Clinically, the change of microbial flora in the reproductive system of a pregnant woman can be rapidly detected, corresponding treatment measures are taken, the risk of PTB occurrence is reduced, and the kit has a good application prospect.

The present disclosure relates, in general, to the methods for the rapid detection of the presence or absence of Lymphogranuloma Venereum (LGV)-causing serovars of Chlamydia trachomatis in a biological or non-biological sample. The methods can include performing an amplification step, a hybridization step, and a detection step. Furthermore, oligonucleotide primers and probes targeting the pmpH gene for the L serovars of Chlamydia trachomatis, along with kits are provided that are designed for the detection of L serovars.

The application provides a primer composition for detecting chlamydia trachomatis, gonococcus and ureaplasma urealyticum and application thereof, and relates to the technical field of nucleic acid determination or detection methods.The primer composition provided by the application comprises a first primer and a second primer for detecting chlamydia trachomatis, a third primer and a fourth primer for detecting gonococcus and a fifth primer and a sixth primer for detecting ureaplasma urealyticum.The primer composition provided by the application can realize the detection of the above-mentioned three pathogens, and has the characteristics of good specificity, high sensitivity and good repeatability.Based on the primer composition, the application further combines an immunochromatography test strip detection technology, so that rapid and efficient detection of chlamydia trachomatis, gonococcus and ureaplasma urealyticum can be realized, the operation is simple and relatively portable, and the primer composition can be used for home self-detection.

The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.

The application provides a primer composition, a kit and application thereof for efficiently detecting common pathogenic bacteria of human, relates to the technical field of microorganism gene detection, and aims at solving the defects of low detection efficiency, poor specificity, low sensitivity of traditional PCR technology, and non-specific amplification of traditional LAMP detection technology. The application designs primers according to known sequences of six common pathogenic bacteria of human, i.e., Candida albicans, Chlamydia trachomatis, Escherichia coli, group B streptococcus, Mycoplasma hominis and Streptococcus pneumoniae, and provides a kit with a micro-fluidic chip as a carrier and application thereof, which are used for detecting common pathogenic bacteria of human, have high specificity and high sensitivity, reduce detection cost and detection time, and can realize on-site rapid detection of common pathogenic bacteria of human.

The invention discloses a chlamydia trachomatis sample collection device, and relates to the technical field of sample collection, the chlamydia trachomatis sample collection device comprises a shell and a built-in groove, the top of the shell is provided with a top plate, the top plate is internally provided with a driving assembly for providing driving force, and the driving assembly comprises an auxiliary plate, a toothed plate and a threaded rod. According to the chlamydia trachomatis sample collecting device, a threaded rod of the driving assembly drives a toothed plate to move, the auxiliary assembly and the flaring assembly can be synchronously linked, the toothed plate is meshed to drive a driving gear to rotate, on one hand, a threaded column is driven to push a swab to move towards a urethral orifice, on the other hand, two sets of racks are driven to move reversely, and a flaring piece completes urethral orifice flaring; the flaring and collecting actions are synchronously carried out, step-by-step operation is not needed, the overall time consumption of sample collection is shortened, the problem of collection failure caused by body position change or instrument displacement in the step-by-step operation process is solved, and the efficiency and success rate of chlamydia trachomatis sample collection are effectively improved.

The invention focuses on a quantum dot microfluidic immunodetection chip and a kit for detecting female genital tract chlamydia trachomatis. The chip comprises a substrate and a cover plate, a sample loading area, a pretreatment area, a reaction area, a detection area and a waste liquid area which are sequentially communicated are formed on the substrate, a plurality of layers of polyelectrolyte-nano magnetic bead self-assembled films are formed in the pretreatment area, an electromagnetic coil is embedded in the cover plate and is aligned with the center of the pretreatment area, and the electromagnetic coil is embedded in the cover plate. A quantum dot anti-MOMP antibody is fixed on the inner wall of a channel of the reaction area, and a photonic crystal microcavity is formed in the detection area. The kit comprises the chip. According to the chip, rapid, high-sensitivity and high-specificity detection of CT is realized through three core innovative designs of a fluorescence enhancement region, an active in-situ pretreatment and enrichment structure and a space-time resolution antibody arrangement structure; meanwhile, a kit containing the chip is provided, the detection convenience and the automation level are further improved, and the application requirements of basic medical institutions are met.

The invention provides a nucleic acid mixed detection method for genital tract chlamydia trachomatis infection, and belongs to the technical field of pathogen detection. The method comprises the following steps: mixing a to-be-detected sample and dividing the sample into six mixed sample pools, and detecting the mixed sample to obtain a positive mixed sample and / or a negative mixed sample; and performing single sample detection on a single sample corresponding to the positive mixed sample. According to the method, 6 mixing (5: 1) is taken as the optimal mixing detection proportion, the sensitivity of mixing detection is 96.70%, and the specificity is 100%; after 9 samples are detected again, the sensitivity is improved to 98.40%, the total coincidence rate is 98.40% (95% CI: 96.5%-100%), and the accuracy requirement of chlamydia trachomatis qualitative detection registration is basically met. The mixed detection technology can increase the number of screened people and the number of positive examples by three times, can save 1 / 3 of reagent cost, and has certain hygienic economic significance.

The invention discloses a composition and a kit for detecting gonococcus, chlamydia trachomatis and ureaplasma urealyticum. The composition comprises a primer pair and a probe corresponding to the primer pair, the primer pair comprises a primer pair 1 and a primer pair 2, wherein the primer pair 1 aims at gonococcus, and the nucleotide sequence of the primer pair 1 is shown as SEQ ID NO.01 and SEQ ID NO.02; the nucleotide sequences of the primer pair 2 aiming at the chlamydia trachomatis are as shown in SEQ ID NO.03 and SEQ ID NO.04; the nucleotide sequences of the primer pair 3 aiming at the ureaplasma urealyticum are as shown in SEQ ID NO.05 and SEQ ID NO.06; the probe comprises: a specific probe 1 aiming at gonococcus, the nucleotide sequence of which is as shown in SEQ ID NO.07; a specific probe 2 for the chlamydia trachomatis, wherein the nucleotide sequence of the specific probe 2 is as shown in SEQ ID NO.08; and the nucleotide sequence of the specific probe 3 aiming at the ureaplasma urealyticum is as shown in SEQ ID NO.09. The requirement of detection sensitivity can be met, and the detection result is high in accuracy; the detection sensitivity can reach 200 copies / mL, and the detection time is less than 35 minutes.

The application discloses a cervical cancer plasma circulating microbial marker combination, a reagent, a kit, a risk assessment model and application thereof, and belongs to the technical field of liquid biopsy and microbiome. The cervical cancer plasma circulating microbial marker combination comprises Prevotella, Sneathia, Chlamydia trachomatis, Peptostreptococcus, Fusobacterium, Campylobacter and Haemophilus. The cervical cancer plasma circulating microbial marker combination is used for verifying cervical cancer patients and healthy people, and the AUC value is 0.939, the sensitivity is 81.58%, the specificity is 90.00%, the accuracy is 85.29%, the positive predictive value is 91.18%, and the negative predictive value is 79.41%, which indicates that the cervical cancer plasma circulating microbial marker combination can effectively distinguish cervical cancer patients from healthy people, is suitable for early screening of cervical cancer, and has significant clinical screening application value.

The present invention relates to a method and system for diagnosing trachomatous ocular diseases using artificial intelligence, the method comprising the steps of: acquiring ocular image data; preprocessing data by cropping an ocular conjunctival region or correcting the brightness and color of an image, and adjusting resolution; fine-tuning a deep learning model to analyze the image, and predicting the presence or absence of trachomatous ocular diseases; and training the deep learning model by using training data and validation data, and evaluating performance.